Study Finds Recent Falls, Inability to Balance on Left Leg Indicate OS Decrease in NHL
Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.
Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.
Patients with non-Hodgkin Lymphoma (NHL) who received treatment with chimeric antigen receptor (CAR) T-cell therapy who have adverse physical performance measures demonstrated worse survival and enhanced risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS), according to a retrospective cohort study presented at the 2025 Tandem Meeting.1
An increased risk of ICANS was observed in patients who recently fell (odds ratio [OR], 5.2; 95% CI, 1.3-20.5; P = .02) and who weren’t able to balance on their left leg for 10 seconds (OR, 2.6; 95% CI, 1.1-6.2; P = .04). On this, presenting author Megan Herr, PhD, an associate member in the Department of Medicine at Roswell Park Comprehensive Cancer Center, said during the presentation, “These 2 measures, together, take less than a minute to implement. They’re easy, they’re cheap, and we can predict who is going to get neurotoxicity.”1
Of patients treated with axicabtagene ciloleucel (axi-cel; Yescarta) who had ICANS vs those who did not, 59% and 55%, respectively, were unable to balance on their left leg for more than 10 seconds. Of those who were treated with tisagenlecleucel (tisa-cel; Kymriah), 82% and 29%, respectively, were unable to balance. Of patients treated with axi-cel who had ICANS and who did not have ICANS, 26% and 0%, respectively, had a recent fall. Of those who were treated with tisa-cel, 27% and 13%, respectively, fell recently.
Patients with an assistive device (HR, 2.6; 95% CI, 1.3-5.2; P <.01), a positive Romberg test (HR, 3.1; 95% CI, 1.2-7.7; P = .02, and less than 5 of 5 strength (HR, 2.3; 95% CI, 1.2-4.5; P = .01) all showed reduced overall survival on an adjusted model. Of patients with elevated CAR-HEMATOTOX scores and at least 2 adverse physical functions, 1-year OS was 9% (P = .0002).
“[Patients who received CAR T] who have adverse physical performance have worse OS and are at higher risk for ICANS. Our proposed scoring system for CAR-T recipients improves identification of patients at risk of these unfavorable outcomes,” Herr stated.
The trial evaluated data from 91 patients who had NHL between 2018 and 2023; 56% of patients were older than 60 years at adoptive cell transfer, 67% were male, 89% were White, 96% had diffuse large B-cell lymphoma, 62% were treated with axi-cel and 38% with tisa-cel, 82% received fludarabine and cyclophosphamide, 72% were treatment resistant at ACT, and 81% had a Karnofsky performance status of 70.
CAR T treatment resulted in complete responses (CR) in 45% of patients and 55% did not achieve a CR, cytokine release syndrome (CRS) of any grade occurred in 64% of patients, ICANS of any grade occurred in 50%, severe ICANS was noted in 18%, and at 1 year, 57% of patients were alive.
Physical function measures included recent falls within the past 6 months, gait speed, strength and motor deficits, the Romberg test, baseline and peak heart rates, assistive device, self-reported pain or neuropathy, balance on right and left legs, and recovery time, among others.
The study authors noted 2 previously established indices that correlate with OS after CAR T-cell therapy—CAR-HEMATOTOX and CT-CI.2,3 CAR-HEMATOTOX established platelets, absolute neutrophil count, hemoglobin, C-reactive protein, and ferritin as indices, and CT-CI established diabetes, hepatic abnormalities, pulmonary dysfunction, renal insufficiency, infection, and body mass index as indices. In both the original paper and in this presented study, the CAR-HEMATOTOX and the CT-CI was not associated with ICANS, however, 1-year OS was associated with CT-CI in the original study but not in this presentation’s study population.
During an X Space hosted by CancerNetwork® during the Tandem Meeting, Shernan Holtan, MD, the chief of Blood and Marrow Transplantation at Roswell Park Comprehensive Cancer Center, stated, regarding this study, “This highlights, that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from the CAR T, and these tests are so simple to do. It’s going to be interesting to see if others can reproduce this.”
References
- Herr M, Betts B, Davila M, et al. Physical function measures identify non-hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Tandem Meeting; February 12-15, 2025; Honolulu, HI. Abstract ID 58.
- Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499-2513. doi:10.1182/blood.2020010543
- Greenbaum U, Hashmi H, Elsawy M, et al. Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART). Blood. 2022;140(Supp 1):4636-4638. doi:10.1182/blood-2022-169452
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
